Literature DB >> 24270348

Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.

Sabrin Husein Albeituni1, Chuanlin Ding, Jun Yan.   

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with suppressive properties that preferentially expand in cancer. Myeloid-derived suppressor cells mainly suppress T-cell proliferation and cytotoxicity, inhibit natural killer cell activation, and induce the differentiation and expansion of regulatory T cells. The wide spectrum of MDSC suppressive activity in cancer and its role in tumor progression have rendered these cells a promising target for effective cancer immunotherapy. In this review we briefly discuss the origin of MDSCs and their main mechanisms of suppression and focus more on the approaches developed up to date targeting of MDSCs in tumor-bearing animals and cancer patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24270348      PMCID: PMC3902636          DOI: 10.1097/PPO.0000000000000006

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  132 in total

1.  Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.

Authors:  Zvi G Fridlender; Jing Sun; Sunil Singhal; Veena Kapoor; Guanjun Cheng; Eiji Suzuki; Steven M Albelda
Journal:  Mol Ther       Date:  2010-08-03       Impact factor: 11.454

2.  Fas-induced caspase denitrosylation.

Authors:  J B Mannick; A Hausladen; L Liu; D T Hess; M Zeng; Q X Miao; L S Kane; A J Gow; J S Stamler
Journal:  Science       Date:  1999-04-23       Impact factor: 47.728

3.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Authors:  Junko Ozao-Choy; Ge Ma; Johnny Kao; George X Wang; Marcia Meseck; Max Sung; Myron Schwartz; Celia M Divino; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

4.  Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.

Authors:  Mélanie Bruchard; Grégoire Mignot; Valentin Derangère; Fanny Chalmin; Angélique Chevriaux; Frédérique Végran; Wilfrid Boireau; Benoit Simon; Bernhard Ryffel; Jean Louis Connat; Jean Kanellopoulos; François Martin; Cédric Rébé; Lionel Apetoh; François Ghiringhelli
Journal:  Nat Med       Date:  2012-12-02       Impact factor: 53.440

5.  High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.

Authors:  Paolo Serafini; Rebecca Carbley; Kimberly A Noonan; Gladys Tan; Vincenzo Bronte; Ivan Borrello
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

6.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

7.  Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.

Authors:  Hequan Li; Yanmei Han; Qiuli Guo; Minggang Zhang; Xuetao Cao
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

8.  Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice.

Authors:  Maciej Kujawski; Marcin Kortylewski; Heehyoung Lee; Andreas Herrmann; Heidi Kay; Hua Yu
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

9.  Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets.

Authors:  Petronela Ancuta; Kuang-Yu Liu; Vikas Misra; Vanessa Sue Wacleche; Annie Gosselin; Xiaobo Zhou; Dana Gabuzda
Journal:  BMC Genomics       Date:  2009-08-27       Impact factor: 3.969

10.  Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.

Authors:  Sergei Kusmartsev; Zhen Su; Axel Heiser; Jens Dannull; Evgeniy Eruslanov; Hubert Kübler; Donna Yancey; Philip Dahm; Johannes Vieweg
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

View more
  24 in total

1.  Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer.

Authors:  Sabrin H Albeituni; Chuanlin Ding; Min Liu; Xiaoling Hu; Fengling Luo; Goetz Kloecker; Michael Bousamra; Huang-ge Zhang; Jun Yan
Journal:  J Immunol       Date:  2016-01-25       Impact factor: 5.422

2.  Induction of liver-specific intrahepatic myeloid cells aggregation expands CD8 T cell and inhibits growth of murine hepatoma.

Authors:  Yung-Chang Lin; Chen-Yu Hsu; Sheng-Kai Huang; Yun-Han Fan; Chien-Hao Huang; Chan-Keng Yang; Wan-Ting Su; Po-Chia Chang; Avijit Dutta; Yu-Jen Liu; Ching-Tai Huang; Tse-Ching Chen; Chun-Yen Lin
Journal:  Oncoimmunology       Date:  2018-09-19       Impact factor: 8.110

3.  The pattern of GPI-80 expression is a useful marker for unusual myeloid maturation in peripheral blood.

Authors:  Y Takeda; T Kato; H Ito; Y Kurota; A Yamagishi; T Sakurai; A Araki; H Nara; N Tsuchiya; H Asao
Journal:  Clin Exp Immunol       Date:  2016-10-04       Impact factor: 4.330

4.  Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model.

Authors:  Xiang Huang; Shiyun Cui; Yongqian Shu
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

Review 5.  Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

Authors:  Stefan Kiesgen; Leonardo Chicaybam; Navin K Chintala; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2017-10-26       Impact factor: 15.609

6.  Inflammation and tumor progression: signaling pathways and targeted intervention.

Authors:  Huakan Zhao; Lei Wu; Guifang Yan; Yu Chen; Mingyue Zhou; Yongzhong Wu; Yongsheng Li
Journal:  Signal Transduct Target Ther       Date:  2021-07-12

7.  Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.

Authors:  Sabine Mueller; Jared M Taitt; Javier E Villanueva-Meyer; Erin R Bonner; Takahide Nejo; Rishi R Lulla; Stewart Goldman; Anu Banerjee; Susan N Chi; Nicholas S Whipple; John R Crawford; Karen Gauvain; Kellie J Nazemi; Payal B Watchmaker; Neil D Almeida; Kaori Okada; Andres M Salazar; Ryan D Gilbert; Javad Nazarian; Annette M Molinaro; Lisa H Butterfield; Michael D Prados; Hideho Okada
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 19.456

8.  Visceral leishmaniasis relapse in HIV patients--a role for myeloid-derived suppressor cells?

Authors:  Rafael Van den Bergh; Jo A Van Ginderachter; Elio Schouppe; Belete A Desimmie; Asrat Hailu; Patrick De Baetselier; Johan van Griensven
Journal:  PLoS Negl Trop Dis       Date:  2014-09-11

Review 9.  The role of myeloid-derived suppressor cells in immune ontogeny.

Authors:  Soren Gantt; Ana Gervassi; Heather Jaspan; Helen Horton
Journal:  Front Immunol       Date:  2014-08-13       Impact factor: 7.561

10.  Mreg Activity in Tumor Response to Photodynamic Therapy and Photodynamic Therapy-Generated Cancer Vaccines.

Authors:  Mladen Korbelik; Judith Banáth; Wei Zhang
Journal:  Cancers (Basel)       Date:  2016-10-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.